200 related articles for article (PubMed ID: 18578541)
1. Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation.
Nieva J; Shafton A; Altobell LJ; Tripuraneni S; Rogel JK; Wentworth AD; Lerner RA; Wentworth P
Biochemistry; 2008 Jul; 47(29):7695-705. PubMed ID: 18578541
[TBL] [Abstract][Full Text] [Related]
2. In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells.
Arosio P; Owczarz M; Müller-Späth T; Rognoni P; Beeg M; Wu H; Salmona M; Morbidelli M
PLoS One; 2012; 7(3):e33372. PubMed ID: 22432016
[TBL] [Abstract][Full Text] [Related]
3. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
Davis DP; Gallo G; Vogen SM; Dul JL; Sciarretta KL; Kumar A; Raffen R; Stevens FJ; Argon Y
J Mol Biol; 2001 Nov; 313(5):1021-34. PubMed ID: 11700059
[TBL] [Abstract][Full Text] [Related]
4. Adduction of cholesterol 5,6-secosterol aldehyde to membrane-bound myelin basic protein exposes an immunodominant epitope.
Cygan NK; Scheinost JC; Butters TD; Wentworth P
Biochemistry; 2011 Mar; 50(12):2092-100. PubMed ID: 21314187
[TBL] [Abstract][Full Text] [Related]
5. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
6. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
7. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
[TBL] [Abstract][Full Text] [Related]
8. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
[TBL] [Abstract][Full Text] [Related]
9. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
10. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
[TBL] [Abstract][Full Text] [Related]
11. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
12. Effects of oxidative post-translational modifications on structural stability and self-assembly of λ6 immunoglobulin light chain.
Zottig X; Laporte Wolwertz M; Golizeh M; Ohlund L; Sleno L; Bourgault S
Biophys Chem; 2016 Dec; 219():59-68. PubMed ID: 27744229
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition.
Vidal R; Goñi F; Stevens F; Aucouturier P; Kumar A; Frangione B; Ghiso J; Gallo G
Am J Pathol; 1999 Dec; 155(6):2009-17. PubMed ID: 10595931
[TBL] [Abstract][Full Text] [Related]
14. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
15. Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?
Morgan GJ; Usher GA; Kelly JW
Biochemistry; 2017 Dec; 56(50):6597-6614. PubMed ID: 29200282
[TBL] [Abstract][Full Text] [Related]
16. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation.
Kim YS; Randolph TW; Manning MC; Stevens FJ; Carpenter JF
J Biol Chem; 2003 Mar; 278(12):10842-50. PubMed ID: 12529361
[TBL] [Abstract][Full Text] [Related]
17. Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains.
Wong S; West ME; Morgan GJ
Protein Sci; 2024 Mar; 33(3):e4871. PubMed ID: 38100259
[TBL] [Abstract][Full Text] [Related]
18. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
19. Human immunoglobulin light chains lambda form amyloid fibrils and granular aggregates in solution.
Bliznyukov OP; Kozmin LD; Vysotskaya LL; Golenkov AK; Tishchenko VM; Samoylovich MP; Klimovich VB
Biochemistry (Mosc); 2005 Apr; 70(4):458-66. PubMed ID: 15892613
[TBL] [Abstract][Full Text] [Related]
20. Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis.
Helms LR; Wetzel R
J Mol Biol; 1996 Mar; 257(1):77-86. PubMed ID: 8632461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
